Good morning, Just a quick reminder, your $150.00 discount and free 30-day trial for MarketBeat All Access expire tonight at 11:59 PM PT. You can still claim full access to our most powerful research tools for just $99.00 (normally $249.00). It’s completely risk-free for the first 30 days, and you can cancel anytime during your trial. Start Your 30-Day Free Trial and Claim Your Discount Why MarketBeat All Access? Smarter Data, Delivered Your Way
Get access to 50+ proprietary data feeds from top brokerages and research firms. Whether you prefer real-time alerts, our premium daily newsletter, or Excel/CSV exports, All Access meets you where you invest. Focus on What Matters
With 500+ analyst ratings released daily, it’s easy to get overwhelmed. Our brokerage rankings cut through the noise, so you only see the firms with a proven track record of accurate calls. Stay Ahead of the Market
Get priority delivery of your daily newsletter plus instant alerts on ratings changes, insider trades, earnings, and more. You’ll never be the last to know. You can try it all for free for 30 days. If it’s not a fit, cancel before the trial ends, and you won’t be charged. Claim Your Free Trial + $150.00 Discount This is your final chance to lock in your savings and experience the full power of MarketBeat All Access. Thanks for being part of the MarketBeat community. I hope you give All Access a try; you might be surprised by what it unlocks. Matthew Paulson
Founder, MarketBeat P.S. Offer expires tonight at 11:59 PM PT. Don’t miss out.
Start Your 30-Day Free Trial Here
This Month's Bonus Story
3 Non-Pharma Firms That Could Benefit From the GLP-1 TrendSubmitted by Nathan Reiff. Originally Published: 6/20/2026. 
Key Points
- With the GLP-1 agonist market still growing at a rapid pace, companies outside of the pharma industry are increasingly likely to benefit.
- Three potentially overlooked beneficiaries of GLP-1s may be TDOC, OLLI, and DXCM.
- TDOC and DXCM are health care firms providing telehealth services and continuous glucose monitoring devices, respectively, while OLLI is a bargain clothing store.
- Special Report: The company SpaceX cannot operate without
The GLP-1 revolution is quietly continuing, even as investor attention has shifted to more timely topics. One of the best ways to access the fast-growing weight loss drug space is through makers like Novo Nordisk (NYSE: NVO) or Eli Lilly (NYSE: LLY), the leading companies behind products such as Ozempic and Zepbound. There are, of course, less direct ways for investors to benefit from the GLP-1 rush as well. The prospect of the market tripling in size in the coming years has enticed a host of other drug developers to pursue their own offerings, and a number of up-and-coming pharma firms may be worth watching. Investors can also look at dedicated exchange-traded funds (ETFs) like the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) for a broader view.
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $29.97 on his website.
Inside, you'll find a 5-part trade framework designed to make every trade a safer one. This free offer won't last - the price goes back to $29.97 soon. Click here to claim your free copy before the offer ends
But the impact of GLP-1 agonists is extending beyond the pharma space, and the companies below could benefit from this trend despite their lack of direct involvement. GLP-1 Telehealth Business Positioned to ThriveTeladoc Health (NYSE: TDOC) operates a telehealth platform that provides patients with virtual care services related to obesity management and metabolic health, among other offerings. These areas of Teladoc's business, along with GLP-1 prescription initiation, are growing particularly quickly. The company makes it as easy as possible for qualified patients to access GLP-1 treatment, which can be a game-changer for those without convenient access to in-person specialists. This has had a real impact on Teladoc's results. In Q1 2026, for instance, the firm beat revenue expectations by about $3 million at $614 million, and adjusted EBITDA of $58 million also came in ahead of guidance. Visit-based care is being enhanced by AI-enabled 24/7 offerings that should remain a sales and margin driver throughout at least the rest of this year. At the same time, Teladoc is working to right its balance sheet by initiating a multi-step debt reduction process and planning to limit stock-based compensation to $55 million or less in the coming year. The firm is also building its financial strength with a cash reserve that reached $751 million at the end of the first quarter. This is a welcome change for investors after several consecutive quarters of shaky financial health, as indicated by a TradeSmith health indicator in the red zone. GLP-1 Customers Buying New Wardrobes Might Fuel This Retailer's GrowthDiscount retailer Ollie's Bargain Outlet (NASDAQ: OLLI) may seem like an unlikely beneficiary of GLP-1 drugs, but this and similar clothing stores could play an increasingly important role for patients losing weight and needing to buy new clothes. Ollie's is among the most aggressive discount clothing retailers in terms of pricing and could be well-positioned to capture business from GLP-1 patients seeking to replace a large number of clothes quickly. For Q1 2026, Ollie's reported strong results overall, including sales growth of 14% year over year (YOY) and comparable store sales improvement of 1.7% over the same period. Adjusted earnings per share (EPS) increased by 21% YOY as well, despite headwinds including inflation and higher fuel prices. Ollie's is also expanding rapidly, with 27 new stores opening in the first quarter of the year and a planned 75 new openings in total this year. OLLI stock is a Moderate Buy across Wall Street, based on 14 Buy ratings and three Holds. Shares have fallen by almost 30% year to date (YTD) but still have about 60% upside potential based on analyst price targets. Glucose Monitoring Devices Could Surge in PopularityAlthough not a pharma company, health care sector peer DexCom (NASDAQ: DXCM) is a medical device firm that could benefit from the GLP-1 trend because of its continuous glucose monitoring (CGM) tools. CGMs are vital for GLP-1 patients with Type 2 diabetes, making these products a useful companion to GLP-1 treatment in some cases. Care providers may increasingly view CGMs and GLP-1s as a combined solution for patients with diabetes. CGMs have long been associated with insulin treatments, but the rapid expansion of GLP-1s beyond the population of patients with diabetes has the potential to create new monitoring needs for people interested in tracking glucose trends even if they are not also using insulin. DexCom has responded by launching over-the-counter products for a wider patient population. Overall, greater awareness of metabolic health and a growing interest in monitoring glucose levels could mean a surge in business for DexCom. This may also help explain DexCom's strong popularity among analysts: the stock has 22 Buy ratings compared to three Holds and one Sell, alongside 17% in predicted upside potential. |
No comments:
Post a Comment